Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sensorion SAS (FR:ALSEN)
PARIS:ALSEN
Holding FR:ALSEN?
Track your performance easily
ALSEN Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.40 - €1.04
Previous Close€0.75
Volume154.32K
Average Volume (3M)47.08K
Market Cap
€224.72M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Mar 13, 2025EPS Estimate
-€0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares OutstandingN/A
10 Day Avg. Volume148,658
30 Day Avg. Volume47,077
Standard Deviation0.26
R-Squared0.09
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)6.27
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.50Price Target Upside234.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment is ongoing in the initial dose escalation cohort in patients 6 to 31 months, and ALSEN remains on track for completion of dosing in the first dose cohort by YE24.
Financial PerformanceSensorion released its 1H24 results, ending the semester with a cash position of €87.3m, providing financial visibility until end-2025.
Regulatory ProgressALSEN plans to request a pre-IND meeting with the FDA by YE24 for inclusion of US sites in the potentially registrational dose expansion portion of the study.
Bears Say
Clinical PerformanceResults of the first 16 patients (out of a total of c. 60) show no difference in hearing loss between the treated and the control arms.
Competitive AnalysisLack of numerical data makes comparison to competitors challenging at this point.
EarningsThis delay for initial proof of clinical efficacy is a disappointment relative to investors’ expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
6.81% Mutual Funds
0.00% Other Institutional Investors
93.19% Public Companies and
Individual Investors
ALSEN FAQ
What was Sensorion SAS’s price range in the past 12 months?
Sensorion SAS lowest stock price was €0.40 and its highest was €1.04 in the past 12 months.
What is Sensorion SAS’s market cap?
Currently, no data Available
When is Sensorion SAS’s upcoming earnings report date?
Sensorion SAS’s upcoming earnings report date is Mar 13, 2025 which is in 168 days.
How were Sensorion SAS’s earnings last quarter?
Sensorion SAS released its earnings results on Sep 18, 2024. The company reported -€0.05 earnings per share for the quarter, beating the consensus estimate of -€0.07 by €0.02.
Is Sensorion SAS overvalued?
According to Wall Street analysts Sensorion SAS’s price is currently Undervalued.
Does Sensorion SAS pay dividends?
Sensorion SAS does not currently pay dividends.
What is Sensorion SAS’s EPS estimate?
Sensorion SAS’s EPS estimate is -€0.06.
How many shares outstanding does Sensorion SAS have?
Sensorion SAS has 300,501,220 shares outstanding.
What happened to Sensorion SAS’s price movement after its last earnings report?
Sensorion SAS reported an EPS of -€0.05 in its last earnings report, beating expectations of -€0.07. Following the earnings report the stock price went down -2.105%.
Which hedge fund is a major shareholder of Sensorion SAS?
Currently, no hedge funds are holding shares in FR:ALSEN
---
Sensorion SAS Stock Smart Score
Company Description
Sensorion SAS
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of innovative therapies to restore, treat and prevent hearing loss. The company's product is in Phase 2 clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies.
---
ALSEN Stock 12 Month Forecast
Average Price Target
€2.50
▲(234.22% Upside)
Technical Analysis
Best Analysts Covering ALSEN
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+44.99%
reiterated a buy rating 3 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +44.99% per trade.
---